Probing
the world's top biotech research institutions, LaunchCyte
acquires technologies that satisfy today's most compelling
health care needs. We license the best of these technologies,
then drive them to market by creating agile, new start-up
companies.
Our
strategy combines the two most valuable investment opportunities
available today — early-stage ventures and life science
technology. Within the life sciences, we focus on molecular
tools and high-throughput systems to accelerate drug discovery
and clinical diagnostics.
>>LaunchCyte portfolio company Knopp Neurosciences Completes First Series B Financing of $10 Million
